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Background
HIV genomic sequence variability has complicated efforts
to generate an effective globally relevant vaccine. Our
strategy for HIV-1 vaccine design is to select epitopes
that can induce broad and dominant HLA-restricted
immune responses targeted to the regions of the viral
genome conserved in sequence, three-dimensional config-
uration, and across time which may represent regions
that are constrained due to functional or structural lim-
itations. These “Achilles’ Heel” epitopes would be ideal
candidates for inclusion in an epitope-based HIV vaccine.
Methods
Highly conserved T-cell epitopes were selected using the
EpiMatrix suite of immunoinformatic tools. This analysis
was first performed in 2002 on 10,803 HIV-1 sequences
available at that time and again in 2009 on an expanded
43,822 sequences. Selected epitopes were validated for
binding and immunogenicity with PBMCs from HIV-
infected donors in Providence, RI and Bamako, Mali.
Results
38 highly conserved HLA-A2 candidate epitopes were
selected. Analysis done in 2009 revealed surprising stabi-
lity of 25 of the epitopes selected in 2002 and identified
an additional 13 highly conserved HLA-A2 candidates.
Thirty-five (92%) of the 38 selected epitopes stimulated
IFNg response in PBMC from at least one subject.
Twenty-one of 25 peptides selected in 2002 were vali-
dated in assays performed in Providence. Eleven (85%) of
the 13 peptides selected in 2009 were confirmed in assays
performed in Mali. Twelve of 18 peptides assayed in both
Providence and Mali were confirmed in both locations.
Conclusion
The validation of these selected HLA-A2 epitopes con-
served across time (2002-to-2009), geography (Provi-
dence and Mali) and clades supports the hypothesis that
these epitopes could provide effective coverage of virus
diversity and would be appropriate candidates for inclu-
sion in a globally relevant HIV vaccine.
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